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Herpes simplex virus type 2 (HSV-2) infection is almost always sexually transmitted, and
causes genital ulceration. Signiﬁcant progress in our understanding of HSV infection has
occurred over the last decade, in part related to the development of accurate and sensitive
laboratory tests to study HSV-2. The application of PCR and type-speciﬁc serology to
individual cases and in population-based studies has enabled the identiﬁcation of a
potentially important role for HSV-2 infection as a cofactor in the sexual transmission of
HIV. This is a particular issue in developing countries. This review describes the
epidemiology of HSV-2 infection in the HIV era, the hypotheses regarding HSV–HIV
interactions, and research priorities for the developing world.
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INTRODUCTION
Herpes simplex virus type 2 (HSV-2) is a double-
stranded DNA virus belonging to the Alphaher-
pesvirinae subfamily [1]. Infection is characterized
by both neural and cutaneomucous tropism [1].
HSV-2 infection is almost always sexually trans-
mitted, and causes genital ulceration. HSV-2
causes a persistent infection which may give rise
to recurrent clinical episodes. Signiﬁcant progress
in our understanding of HSV infection has
occurred over the last decade, in part related to
the development of accurate and sensitive labora-
tory tests to study HSV-2 [2]. The application of
PCR and type-speciﬁc serology to individual cases
and in population-based studies has enabled the
identiﬁcation of a potentially important role for
HSV-2 infection as a cofactor in the sexual trans-
mission of HIV. This is a particular issue in devel-
oping countries. It has been established that
genital HSV-2 infection is frequently unrecog-
nized, and that asymptomatic HSV-2 shedding
may be important for transmission [3]. Commer-
cial type-speciﬁc serology assays have become
available, allowing population-based serologic
surveys of HSV-2 infection, which have shown
that: (1) HSV-2 prevalences are high in some
Western countries and very high in developing
countries; (2) the global prevalence of genital HSV-
2 has probably increased during the past 10 years;
and (3) HSV-2 seropositivity may be a useful
marker of high-risk sexual behavior in some set-
tings. Inmany countries in Sub-SaharanAfrica, the
HSV-2 epidemic has spread in parallel with the
HIV epidemic. This review describes the epide-
miology of HSV-2 infection in the HIV era, the
hypotheses regarding HSV–HIV interactions, and
research priorities for the developing world.
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HSV-2 INFECTION: A GROWING
PUBLIC-HEALTH PROBLEM
Natural history of genital herpes
Most HSV infections are unrecognized. Suscepti-
ble individuals develop primary infection after
their ﬁrst exposure to either HSV-1 or HSV-2.
Genital herpes infections can be associated with
serious morbidity. First-episode genital herpes
can cause painful ulcerative lesions and systemic
manifestations, including headache, malaise, and
fever lasting up to 3weeks [2]. Complications in
men are rare; aseptic meningitis and urinary reten-
tion aremore common inwomen [1]. In addition to
the latent state, subclinical or ‘asymptomatic’
infectious viral shedding is frequent [3]. The med-
ian recurrence rate after a symptomatic ﬁrst epi-
sode of genital herpes is four-to-ﬁve episodes/
year. Patients who suffer severe ﬁrst episodes
have even higher recurrence rates [4]. Studies
have demonstrated that many or most seroposi-
tive persons shed HSV-2 that is detectable by
culture from the genital tract, and many have
symptoms, such as itching and discharge, that
are directly referable to HSV-2 detectable by
culture [3,4]. Such symptoms, however, are not
often recognized as indicating an infection [5,6].
In most studies, the proportion of infections that
are both symptomatic and recognized (by patient
and clinician) varies between 13% and 37%. This
proportion is higher among HIV-positive indivi-
duals.
Transmission and acquisition of HSV-2
infection
HSV-2 infections are almost always sexually trans-
mitted. Most genital HSV infections are caused
by HSV-2; however, an increasing proportion is
attributable to HSV-1 [2]. Prospective studies of
HSV-2-discordant partners have shown that
most transmission events are not associated with
clinically recognized HSV-2 recurrence in the
infected partner [5,7]. As for other sexually trans-
mitted diseases (STDs), the risk of acquisition of
HSV-2 seems to be higher in women than in
men [5,7,8]. This increased risk of acquisition of
HSV-2 may relate to the higher number of HSV-2
recurrences in infected men (about 20% higher
than in women) [9]. It may also be related to
biological factors, such as the larger and more
vulnerable genital mucosal surface of women
[10,11].
Extent and frequency of subclinical shedding
of HSV-2
Data have recently been accumulating, mainly
from the USA, emphasizing the frequency of sub-
clinical HSV-2 shedding and its role in the trans-
mission of HSV-2 infection to sexual partners
and neonates [12–14]. These studies have shown
that the level of virus required to infect the
neonate can sometimes be low [15]. Although it
is not known what proportion of new disease
acquisitions (outside these groups) is related to
subclinical shedding, it is likely to contribute to
the spread of HSV-2 disease [14]. Reported rates
of subclinical shedding vary widely between stu-
dies [14]. Shedding from internal and external
genital, perineal and perianal sites is frequent
[3,16,17].
The frequency of clinical recurrence and asymp-
tomatic shedding is signiﬁcantly lower in HSV-1
genital infection than in HSV-2 infection [14].
There is no difference in shedding rates between
those individuals who are seropositive for HSV-2
alone and those who are positive for both HSV-1
and HSV-2 [14]. The frequency of subclinical shed-
ding rises with the number of clinical attacks,
although this association may be lost with a low
number of lesions [18]. Moreover, the frequency
of subclinical shedding is highly dependent on
the methodology used for detection. Multiple-site
swabbing and the application of highly sensitive
methods, such as PCR assays, have increased
theyield [3]. PCRdetectionhas shown that thevirus
may be present on mucocutanous surfaces up to
3.5 times more often than previously found by
culture [3,19]. Such virus is predominantly asso-
ciated with subclinical shedding [14]. Quantitative
PCR shows that, overall, the HSV DNA titer tends
to be higher on lesional days than on non-lesional
days [3].
Epidemiology of HSV and HSV-related
genital ulcers
Developed countries
It has been recognized for decades that HSV is
transmitted sexually [20]. Both HSV-1 and HSV-2
can cause primary genital herpes, with HSV-1
accounting for nearly half of the cases in some
centers [21]. In Western countries, HSV-1 rates
in childhood are dropping [22], and many
adolescents are infected with HSV-1 as a result
of their ﬁrst exposure to the virus during sexual
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activity (infection acquired by genital–genital con-
tact or by oral–genital contact) [23]. Nevertheless,
HSV-1 reactivates less frequently from latency in
sacral ganglia than HSV-2, so most episodes of
recurrent genital herpes are caused by HSV-2
[20,24].
A population-based study in the USA reported
that, in 1996, 22% of adults were seropositive for
HSV-2 [25]. This ﬁgure had increased by about
30% since a previous similar survey a decade
earlier [26], despite widespread health education
programs in the 1980s and 1990s on the importance
of ‘safe sex’ in response to the HIV epidemic [27].
Between 1988 and 1994, 45 million people were
estimated to have acquired HSV-2 infection [25];
this represents one in ﬁve people over the age of
12 years. The HSV seropositivity rates in HIV-
infected persons are even higher. Hook et al. in
Baltimore, USA, found an HSV-2 seroprevalence
rate of 81% among HIV-positive homosexual or
bisexualmen [28]. Indeed, genital herpes transmis-
sion appears to be epidemic within the USA. Other
countries have been slower to document the extent
of HSV exposure, but it is becoming apparent that
the HSV-2 epidemic has pandemic proportions
[20].
Developing countries
In Sub-Saharan Africa, epidemiologic studies of
HSV-2 have found high seroprevalence rates in a
range of adult populations: 40% in Kinshasa [29],
40% in Zimbabwe [30], 30–50% in South Africa
[31], 51% in Rwanda [32], 67% in Tanzania [33],
68% in Uganda [32], and even higher levels in the
Central African Republic (82%) [34]. These rates
demonstrate that HSV-2 is a common genital infec-
tion in Africa. Infection with HSV-1 is endemic in
these populations, and is mostly acquired in child-
hood [33–35]. HSV-2 prevalence rises rapidly in
adolescents who are sexually active [36], and
increases with age [33]. In Asia, HSV-2 seropreva-
lences range from 6% in general populations to
50% in high-risk groups [36]. The low rate of HSV-
2 in young versus old Chinese women can be
explained by the effective control of sexually trans-
mitted infections after the revolution [36], whereas
the low rates of HSV-2 seroprevalence in some
isolated tribes in Brazil suggest recent introduction
of the virus [36].
Numerous epidemiologic studies clearly de-
monstrate that chancroid, syphilis and genital
herpes are all common causes of genital ulcer
disease (GUD) in developing countries [37]. How-
ever, there is some evidence that there have been
changes in the etiology of GUD during the past 10
years, in parallel with the spread of the AIDS
epidemic [32], and this may affect the impact of
current syndromic management. A prospective
study in South Africa from 1986 to 1998 showed
that the proportions of GUD due to chancroid and
syphilis decreased during the study period [37]. Of
the 239 GUD cases diagnosed in 1986, 53% were
chancroid and 12% syphilis. By 1998, 33% and 3%
of 200 GUD cases were chancroid and syphilis,
respectively. In parallel, a rapid increase in the
proportion of herpetic ulcers, in both HIV-positive
and -negative subjects, was noted in the same
setting (3/239 (1%) in 1986, and 47/200 (24%) in
1998 [37]).
HSV-2 as a marker for sexual behavior
An association between HSV-2 infection and
reported sexual behavior has been observed in
studies performed in industrialized countries
[26,36,38]. Thus, a good correlation between the
prevalence of HSV-2 antibodies and the number of
lifetime sexual partners, particularly in men, has
been observed [36]. It also appears that, with an
equal number of sexual lifetime partners, women
will have a higher prevalence of HSV-2 antibodies
than men [36].
In contrast to studies in industrialized countries,
Obasi et al. found no signiﬁcant association with
age at ﬁrst intercourse [33]. In this study, HSV-
2-infected persons were more likely to report
higher numbers of sex partners. Furthermore,
the trend for increasing prevalence of infection
with increased number of lifetime partners was
statistically signiﬁcant for both men and women,
even after adjustment for age and residence [33].
HSV-2 serology may be a useful objective biologi-
cal marker for changes in sexual behavior in
HIV intervention studies, since HSV-2 is more
readily transmitted sexually than HIV. However,
given the persistent nature of the infection,
seroprevalence will be more discriminating in
younger age groups [33]. Therefore, HSV-2 seroin-
cidence would be a preferable marker of behavior
change, especially in countries in Sub-Saharan
Africa, where there is high incidence among young
people.
Indeed, the recent study of Auvert et al.
among youths in Carletonville (South Africa)
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demonstrated that HIV infection was associated
with HSV-2 seropositivity and sexual behavior
[31]. The strong association between HIV infection
andHSV-2 seroprevalence, and the fact that HSV-2
infection was a frequent cause of genital ulcers,
indicated that HSV-2 could play a major role in the
spread ofHIV in the population of young people of
South Africa [31].
GENITAL HSV-2 AS A POSSIBLE
COFACTOR OF HIV INFECTION
STDs: cofactors of sexual transmission
of HIV
Epidemiologic [39–41] and intervention studies
[42,43] in Sub-Saharan Africa have demonstrated
the role of STDs in facilitating the acquisition and
transmission of HIV. This has provided a strong
argument for making STD control an integral
part of HIV prevention strategies [29,43,44]. In
fact, STDs that cause genital ulceration, such as
syphilis, chancroid, and HSV-2 infection, are espe-
cially implicated in facilitating HIV transmission
[17,28,30,41,45–47]. GUD is believed to increase the
risk of HIV acquisition per sexual exposure by
increasing the amount of HIV shedding through
genital lesions and by providing an easier portal of
entry for the virus into the host [30,48]. These
ﬁndings have been supported by recent biological
studies that have shown the role of certain STDs,
such as gonorrhea and genital ulcers, in men [49]
and in women [50,51] in enhancing HIV shedding
[49].
Although GUD is a common complaint in STD
clinics in Africa, screening for and management of
HSV-2 is rarely done [30]. Nevertheless, studies
have found that HSV-2 is common among STD
clinic attendees in Africa [52]. For example, in
Kampala, HSV-2 was present in 36% of GUD
patients [53]. In a study that screened sera from
Dakar, the prevalence of HSV-2 ranged from 20%
among surgical patients to 96% among prostitutes
[23]. High prevalences of HSV-2 were also
recorded in rural populations of Uganda and
Tanzania [33,35]. Taking into account the high
prevalence levels of HSV-2, the increased shed-
ding of HIV through genital herpes lesions, and
the fact that persons with HSV-2 remain poten-
tially infectious for life, HSV-2 may make an
important contribution to HIV transmission in
Africa [30].
Bi-directional interaction between HSV-2
and HIV
In their review of available data on the role of STDs
in the sexual transmission of HIV infection, Flem-
ing and Wasserheit [39] group the evidence that
STDs facilitate the transmission of HIV into three
categories: (1) biological plausibility studies; (2)
HIV seroconversion studies; and (3) community-
level intervention studies. While there is ample
evidence for the role of ulcerative and non-ulcera-
tive bacterial STDs in enhancing HIV transmission
and acquisition, little is known about the relation-
ship between HIV and viral STDs such as HSV
infection.
Biological plausibility suggesting interactions
between HSV-2 and HIV
During sexual intercourse, genital ulcers may
bleed, leading to an increased risk of HIV trans-
mission. Studies of HIV-infected people with GUD
suggest that GUD may increase infectiousness, as
HIV proviral DNA has been detected in genital
ulcer exudates [54]. Similarly, Schacker et al. [47]
provided further evidence to support the hypoth-
esis that genital herpes infection increases the
efﬁciency of the sexual transmission of HIV-1. In
their study, HIV RNAwas consistently detected in
genital ulcers caused by HSV-2 in HIV-1-seropo-
sitive men in Seattle [47]. Moreover, treatment or
healing of GUDwas accompanied by a decrease in
HIV shedding [47]. An increased viral load and the
proximity of virions to cutaneous surfaces are
factors that may lead to the increased transmission
of HIV in the presence of HSV [47].
AmongHIV-negative people, GUDmay increase
susceptibility by disrupting mucosal integrity,
leading to the recruitment and activation of HIV
target cells. There is also evidence that: (1) among
‘asymptomatically’ HSV-2-infected patients (i.e. in
the absence of visible ulcer), HSV-2 genital shed-
ding is increased in HIV positives [17,34]; and (2)
both HIV RNA and HSV-2 DNA shedding are
increased in the presence of the other virus [34].
Another study also demonstrated that HSV-2 reac-
tivation is associated with an increase in plasma
HIV-1 RNA and intracellular gag mRNA, and that
plasma HIV-1 RNA levels decrease signiﬁcantly
during treatment with acyclovir [55]. Kucera et al.
[56] reported that co-infection of human CD4þ
cells with HSV and HIV results in accelerated
replication of HIV.
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Similarly, Heng et al. [57] found that the upre-
gulation of HIV-1 expressionwas induced byHSV,
and this may translate to increased plasma HIV-1
RNA levels. Their study documented in vivo reci-
procal enhancement of viral replication associated
with the co-infection of keratinocytes and macro-
phages by HIV-1 and HSV-1 in patients with AIDS
and HSV lesions. Indeed, their observation may be
evidence of the importance of including anti-her-
petic drugs as part of the overall treatment of
patients with AIDS to avoid the excessive replica-
tion of HIV-1 in both CD4þ-dependent and -inde-
pendent targets [27]. In addition, a recent study
found that the inclusion of acyclovir with antire-
troviral therapy may prolong survival in HIV-
seropositive individuals [27]. Furthermore, Rando
et al. [58] showed that HIV long-terminal repeat
(HIV LTR) is activated by herpesviruses as
measured by HIV LTR-directed expression of
the acetyltransferase gene (CAT). Other studies
have also demonstrated that alpha and beta genes
of HSV are responsible for the transactivation of
HIV gagLTR [59–62].
As a result, it is possible that HIV progresses
more rapidly in untreated HSV-2-positive indivi-
duals. However, the evidence is inconclusive, and
more studies of the effect of episodic HSV-2 ther-
apy on HIV are needed, especially in developing
countries. The impact of HIV on HSV, with regard
to the clinical reactivation of HSV, the role of
immunosuppression, and the possible frequency
of asymptomatic carriage, remains, however, lar-
gely undetermined.
Studies of HIV incidence in patients with genital
ulcers due to HSV-2 or HSV-2 seropositivity
Eight studies of HIV incidence in high-risk indi-
viduals assessed the role of genital HSV-2 in the
sexual transmission of HIV [39], including ﬁve
studies on homosexual men [45,63–66].
Only three studies have investigated the role of
HSV in heterosexual transmission of HIV infection
[67–69]. In two studies, the rate of HIV seroconver-
sionwas higher among individuals whowereHSV
seropositive. In a case–control study of Thai mili-
tary conscripts, HSV antibodies were three times
more common in HIV seroconverters than in
men who remained HIV negative (OR 3.1, 95%
CI 1.2–7.9) [68].
The second cohort study, also in Thailand mili-
tary conscripts, found a fourfold increase, which
was statistically signiﬁcant, in the relative risk of
HIV seroconversion among those who were HSV
seropositive [69]. However, the relative risk was
2.0 (95% CI 0.6–6.1) after adjustment for sexual
behavior. A study of STD patients inNewYork did
not ﬁnd increased HIV seroconversion to be asso-
ciated with HSV infection [67]. In this latter study,
HSV infection was diagnosed by clinical examina-
tion and Tzanck cytodiagnosis, so many HSV
infections may have been missed.
There are three nested case–control studies that
have investigated the role of HSV infection in
male-to-male transmission of HIV [45,63,64].
Holmberg et al. observed that the risk of HIV
seroconversion was two times greater in men
who were HSV-2 seropositive than in those who
were seronegative, and that HSV-2 seroconverters
were at even greater risk of HIV seroconversion
(OR¼ 6.0) [45]. Keet et al. also found an association
between HIV acquisition andHSV-2 seropositivity
[63]. However, no association was found in the
study by Kingsley et al. [64].
Seroconversion studies are likely to underesti-
mate the effect of HSV-2 on HIV transmission.
First, HSV causes a chronic disease, and recur-
rences decrease over time. Second, HSV seroposi-
tivity does not correlate well with clinical
episodes. Third, the methods used to measure
HSV are often insensitive. Finally, there is often
failure to adjust for the usual confounders, such as
sexual behavior or other STDs.
Epidemiologic data showing an association
between HIV and HSV-2 seropositivity in Africa
have been scarce [30,33,34]. A multicenter study
assessed parameters which could explain the het-
erogeneity of HIV epidemics in four African cities
characterized either by high HIV prevalences (20–
30% in Kisumu, Kenya and in Ndola, Zambia) or
by low HIV prevalences (3–8% in Cotonou, Benin
and in Yaounde, Cameroon) [70]. This study
showed an association between HIV and HSV-2
infection [70]. In fact, the authors of this study
demonstrated that cities with high HIV prevalence
also have high HSV-2 prevalence. This association
is particularly strong among the youth population.
Weiss et al. showed a strong association between
HSV-2 prevalence and seropositivity for HIV (OR
5–10) after adjustment for sexual behavior [70].
Another study of 2397 adults inHarare, Zimbabwe
showed an HSV-2 prevalence of 39.8%, and an
incidence of seroconversion for HSV-2 of 6.2 per-
sons/year, without a clear association with the
risk of seroconversion for HIV [71].
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Lack of intervention studies focused on
genital herpes
The demonstration of any bi-directional and/or
synergistic interactions between STDs and HIV
infection, added to the fact that HIV infection is
an STD, has direct public-health implications [29].
Intervention studies in Africa [29] and in Thailand
[72], combining preventive interventions and
treatment of STDs, demonstrated that it may be
possible to reduce the incidence of HIV infection in
the developing world. Furthermore, the Mwanza
study in Tanzania demonstrated that improved
STD case management was an important addi-
tional HIV prevention strategy [43], resulting in
a 40% reduction in HIV incidence in the general
population. No such reduction was achieved by
STD mass treatment in the Rakai study in Uganda
[44], and one reason postulated for this was a
higher prevalence in Rakai of STDs such as genital
herpes that were not targeted by the antimicrobial
regimen [73].
Indeed, there are few intervention studies to
date documenting an impact of anti-HSV-2 treat-
ment on HIV transmission. The Schacker study on
12 men in Seattle is the only study to have docu-
mented that treatment or healing of GUD caused
by HSV-2 was associated with a reduction of HIV
shedding. Even in this instance, it was unclear
whether the effect was spontaneous or due to
any speciﬁc intervention [47].
RESEARCH PRIORITIES FOR THE
DEVELOPING WORLD
Biological interactions between HSV-2 and HIV
There is an urgent need for more studies to assess
the burden of clinical disease due to HSV-2 in
different settings. These studies may also contri-
bute to a better understanding of the biological
mechanisms that underlie the HSV-2–HIV inter-
action, and provide biological endpoints for
further intervention trials.
HSV-2 treatment trials
In order to determine whether HSV-2 enhances
HIV shedding and transmissibility, randomized
intervention studies will be necessary, preferably
in settings with high HSV-2 seroprevalence (and
shedding) and high HIV seroprevalence and/or
incidence. It is accepted that a randomized, con-
trolled trial of interventions could provide the
most convincing evidence to demonstrate this
relationship.
The aim of such intervention studies should
therefore be to decrease HIV shedding in indivi-
duals co-infected with HIV and HSV (and ideally
also HIV incidence in HIV-negative partners). This
decrease should in theory be mediated by an
observed decrease in HSV-2 shedding (i.e. preva-
lence or duration of shedding and/or quantity of
virus particles shed) or lesions apparent or inap-
parent.
Two types of studies should be considered:
episodic treatment of GUD, by adding acyclo-
vir/valacyclovir to the syndromic management
versus placebo and measuring the effect on
HSV-2 and HIV shedding; and suppressive ther-
apy with acyclovir/valacyclovir (the latter drug is
preferable because of its single daily dose) of HIV/
HSV-2-infected individuals to prevent HSV reac-
tivation.
Effects of HSV-2 therapy on HIV shedding
and transmission
HSV-2 antiviral therapy has been shown to
decrease HIV shedding from herpetic lesions in
individuals co-infected with HSV-2 and HIV.
However, there are no studies demonstrating a
reduction in the rate of HIV seroconversion.
Therapy to prevent herpetic disease
Although there are currently no data available,
there is a biological rationale for therapy in
HSV-2-negative individuals. This would aim at
preventing herpetic disease rather than infection.
Because the ﬁrst episode of disease would be
aborted, fewer latent copies should, in theory, be
present in the ganglia for reactivation, and this
should limit the frequency of recurrences. A
further consideration is that the practicalities of
prophylactic therapy make it unlikely to be feasi-
ble on a large scale in developing countries. How-
ever, its use could be considered in speciﬁc groups
at high risk of HIV infection, such as HIV-negative
members of discordant couples, sex workers, and
possibly, young women.
Viral resistance
It has been reported that HSV can develop resis-
tance to acyclovir through mutations in the viral
gene that encodes thymidine kinase, by generation
of thymidine-kinase-deﬁcient mutants, or by selec-
tion of mutants with a thymidine kinase unable to
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phosphorylate acyclovir [1]. Resistant HSV occurs
more frequently among HIV-infected patients,
probably due to increased replication of HSV
and decreased immunity in these patients [27].
Toxicity
Continuous acyclovir therapy has not caused
long-term toxicity in the past decade [1].
Genital mucosal immunity to HSV-2 infection
The control of HSV latency is not understood, but
mucosal immune responses against HSV are likely
to be important in the control of mucosal lesions.
Studies in a mouse model on host resistance to
HSV-2 have shown that vaginal infection with an
attenuated HSV-2 strain induces protective immu-
nity to subsequent lethal challenge with wild-type
virus. Both cell-mediated and humoral local
immunity, mainly of the IgG or IgA isotype, have
been described [74,75]. Furthermore, T-cell-
mediated immunity at themucosal level is thought
to play a major role in the resolution of recurrent
HSV infection in animal models [76]. The cellular
immunity to HSV is thought to assist in limiting
secondary genital HSV-2 infection [5]. Antibodies
to HSV of both the IgA and IgG isotypes have been
detected in cervicovaginal secretions of women
with vaginal discharge [77], and in women suffer-
ing from primary herpetic genital infection [78,79]
or reactivation [78]. However, little is known about
their functional properties. Studies to localize neu-
tralizing activity to puriﬁed cervical IgG, IgA or
IgM components would be useful.
Vaccination against HSV-2
Given the high prevalence of HSV-2 infection in
many countries, and the fact that most infections
are subclinical, the development of an effective
HSV-2 vaccine would provide a powerful control
tool.
Most vaccination strategies against herpes sim-
plex virus have focused on the development of
subunit vaccines that consist of one or more HSV
glycoproteins [80]. In fact, studies have shown that
vaccination of mice with puriﬁed glycoprotein D
(gD) provides protection against a lethal intraper-
itoneal challenge of HSV, and vaccination of gui-
nea pigs with recombinant gD or gB protects
against intravaginal HSV-2 infection [81,82]. Clin-
ical trials indicate that puriﬁed gD has induced
neutralizing antibody responses in previously
uninfected persons and boosted the antibody
response in patients with genital herpes [83].
Three HSV-2 vaccines have been recently eval-
uated in clinical trials.
Recombinant glycoprotein vaccine gB2 and gD2
with MF59
This subunit HSV vaccine is no longer in commer-
cial development. Phase I studies showed that it
was well tolerated and induced speciﬁc neutraliz-
ing antibody and T-cell lymphoproliferation
responses comparable to or higher than those seen
in HSV-2-infected subjects. Two phase III trials
have assessed the effectiveness of the vaccine in
the prevention of HSV-2 infection. Survival ana-
lysis showed a short-term efﬁcacy of 50% for the
ﬁrst 5 months of follow-up, but, thereafter, the
effect disappeared [84]. The overall efﬁcacy was
9% (95% CI 29% to 36%), although substantial
differences were observed in men and women
( 4% in men and 26% in women). Vaccination
had no signiﬁcant inﬂuence on duration of the ﬁrst
clinical episode of genital HSV-2, or on the sub-
sequent frequency of recurrence. The authors con-
cluded that efﬁcient and sustained protection
against sexual acquisition of HSV-2 infection
would require more than high titers of speciﬁc
neutralizing anitbodies and, as the vaccine pro-
vided only transient protection against HSV-2
infection, work has been halted [84].
Recombinant glycoprotein vaccine gD2 with
adjuvant SBAS4
This subunit HSV vaccine is in commercial devel-
opment and, again, induced HSV-speciﬁc anti-
body and cell-mediated immune responses in
phase I studies. Two phase III trials assessed
vaccine efﬁcacy in the prevention of genital HSV
disease, with secondary assessment of prevention
of HSV-2 infection [85]. The vaccine induced sig-
niﬁcant protection (approximately 70% efﬁcacy)
against genital herpes disease in womenwhowere
initially HSV-1 and HSV-2 seronegative. Trends
towards protection of women against HSV infec-
tion were also seen in both studies (39–48% efﬁ-
cacy), although these were not statistically
signiﬁcant. In contrast, there was no evidence of
protection in women who were initially HSV-1
seropositive, or in men. The main disadvantages
of this vaccine are the apparent failure to improve
on the protection provided by HSV-1 infection,
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and the need for frequent vaccine administration
to boost host immunity.
Disabled infectious single-cycle (DISC)
HSV-2 vaccine
Phase I studies have shown that this vaccine is well
tolerated and induces neutralizing antibody and
lymphoproliferative responses comparable to
those seen in HSV-2-infected subjects [86].
Eighty-three per cent of vaccine recipients devel-
oped HSV-speciﬁc cytotoxic T-lymphocyte
responses. Phase II efﬁcacy trials are underway
in the USA andUK to assess the efﬁcacy of DISC as
a therapeutic vaccine in the treatment of frequently
recurrent genital HSV-2 infections. Because of its
high content of HSV-2 virion, this product may
improve on the natural protection provided by
HSV-1. However, the similarity of its effects to
those of HSV-2 infection means that it would
not be possible to distinguish natural infection
from vaccine-induced immunity. The main disad-
vantages of the DISC therapeutic vaccine are that it
needs to be administered at least 6-monthly, it is
expensive, and it needs further development.
Nevertheless, partnerships should be sought to
enable the DISC vaccine to be taken to the next
stage of development [86]. In addition, vaccine
trials to evaluate the efﬁcacy of a therapeutic
HSV-2 vaccine should be part of today’s research
agendas [86].
CONCLUSION
In the face of the severe and worsening HIV-1
epidemic in Africa, the high prevalence of HIV-1
and HSV-2, and the high frequency of asympto-
matic HSV-2 shedding, a possible synergistic effect
between the infections is a cause for concern. We
have learned in the past decade that no single
approach will contain the HIV/AIDS epidemic,
and we need to consider all available means of
control, however imperfect. There is an urgent
need for further research on genital herpes and
STD/HIV control in Africa. These studiesmay also
help us to better understand the biological
mechanisms that underlie the HSV-2–HIV inter-
action, and provide biological endpoints for
further intervention trials. Studies on patients
with GUD and HIV will be necessary to ﬁnd
whether episodic therapy with acyclovir or
another prodrug hastens the healing process,
thereby decreasing HIV andHSV-2 shedding. This
may lead to revision of current syndromic man-
agement practices in developing world settings.
We also need to develop and test preventive inter-
ventions, particularly those targeting youths.
However, it may be that the most realistic hope
for control is the development of a safe and effec-
tive HSV-2 vaccine.
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